Patients' Perspective, Quality of Life and Treatment Goals in Hailey-Hailey Disease: lessons learned from the German National Registry

J Eur Acad Dermatol Venereol
20 October 2023
https://pubmed.ncbi.nlm.nih.gov/37863661/

Background: Hailey-Hailey disease (HHD) remains a difficult-to-treat dermatosis and little is known about the patient's perception of the disease activity, the treatment success, and its impact on quality-of-life (QoL).

Low-dose naltrexone as treatment for epidermolysis bullosa pruriginosa-associated refractory pruritus

Case Reports; JAAD Case Rep
19 June 2023
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339115/

Welcome to the LDN Radio Show brought to you by the LDN Research Trust. I'm your host Linda Elsegood. Today we're joined by Ray Solano from PD Labs. He's also a nutritionist. Could you tell us a bit of background about yourself?

Topical Steroid Withdrawal (TSW)

There is a need to raise awareness about Topical Steroid Withdrawal (TSW), a serious potential side
effect of topical steroid use. TSW is not always recognized by patients or practitioners as much is still
unknown about this consequence of using topical steroids, particularly long term.¹

What are skin conditions?

Dermpath & Clinic: Hailey Hailey disease treated with low-dose naltrexone

Eur J Dermatol
01 October 2021
https://pubmed.ncbi.nlm.nih.gov/34903509/

Cases of patients with Hailey-Hailey disease treated with low-dose naltrexone who achieved resolution of symptoms suggest low-dose naltrexone is an effective novel therapy for Hailey-Hailey disease.

Darier and Hailey-Hailey disease: update 2021 (Abstract) (LDN, low dose naltrexone)

J Dtsch Dermatol Ges
October 2021
https://pubmed.ncbi.nlm.nih.gov/34661345/

Anne-Maree - Australia: Hailey-Hailey Disease (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.